OPKO Health, Inc. (NASDAQ:OPK) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of OPKO Health, Inc. (NASDAQ:OPK) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $2.6250.

Several research analysts have recently commented on OPK shares. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research note on Wednesday, October 8th. LADENBURG THALM/SH SH upgraded shares of OPKO Health to a “strong-buy” rating in a research note on Tuesday, July 8th. Finally, Zacks Research upgraded shares of OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th.

Insider Activity

In other news, CEO Phillip Md Et Al Frost acquired 675,000 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average cost of $1.32 per share, with a total value of $891,000.00. Following the acquisition, the chief executive officer owned 214,676,448 shares in the company, valued at approximately $283,372,911.36. This represents a 0.32% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 49.69% of the company’s stock.

Institutional Trading of OPKO Health

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of OPKO Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 29,500,071 shares of the biotechnology company’s stock worth $48,970,000 after buying an additional 293,740 shares during the period. Sculptor Capital LP bought a new stake in shares of OPKO Health during the 1st quarter worth $21,111,000. Geode Capital Management LLC boosted its holdings in shares of OPKO Health by 23.7% during the 2nd quarter. Geode Capital Management LLC now owns 10,424,473 shares of the biotechnology company’s stock worth $13,763,000 after buying an additional 1,995,633 shares during the period. Millennium Management LLC boosted its holdings in OPKO Health by 39.2% in the 1st quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 1,798,385 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in OPKO Health by 4.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,001,214 shares of the biotechnology company’s stock valued at $6,642,000 after purchasing an additional 161,394 shares during the period. 64.63% of the stock is owned by institutional investors.

OPKO Health Stock Up 1.3%

OPKO Health stock opened at $1.52 on Friday. The firm’s 50 day moving average price is $1.44 and its two-hundred day moving average price is $1.38. OPKO Health has a twelve month low of $1.11 and a twelve month high of $2.04. The firm has a market cap of $1.21 billion, a PE ratio of -6.08 and a beta of 1.50. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.02 and a current ratio of 3.41.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.07). OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%.The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $165.74 million. During the same quarter last year, the company earned ($0.01) EPS. The business’s revenue for the quarter was down 13.9% compared to the same quarter last year. On average, research analysts predict that OPKO Health will post -0.25 EPS for the current fiscal year.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.